

RENERGEN LIMITED

Incorporated in the Republic of South Africa
(Registration number: 2014/195093/06)
JSE Share Code: REN
A2X Share Code: REN
ISIN: ZAE000202610
LEI: 378900B1512179F35A69
Australian Business Number (ABN): 93 998 352 675
ASX Share code: RLT
("Renergen" or "the Company")



PRODUCTION OF THE FIRST CRYO-VACC™ COMMENCE FOR DPD LASER

Domestic natural gas and helium producer Renergen Limited ("Renergen or the "Company") and DPD Laser (Limited) ("DPD Laser") have entered into an agreement for the manufacture and purchase of the first 110 Cryo-Vacc™ cases, following the launch of Renergen's Cryo-Vacc™ storage solution (see ASX announcement dated 15 February 2021).

DPD Laser is one of South Africa's leading express courier companies that has been proudly serving South Africa for over 30 years.

The key terms of the agreement with DPD Laser are:

- The agreement relates to a fixed purchase of 110 Cryo-Vacc™ cases in a combination of all three sizes; and
- The Cryo-Vacc™ cases will be delivered in May.

There are no other material conditions to the agreement.

Whilst the agreement with DPD Laser is not considered material to the Company from a revenue perspective, it represents a significant milestone for the Company regarding the commencement of manufacturing of the Cryo-Vacc™ to its customers.

The agreement has been completed ahead of the launch of Phase 2 vaccination program for SA. Renergen has commenced construction of the 110 Cryo-Vacc™ cases for delivery to DPD Laser, which is expected to be completed by the end of May 2021.

DPD Laser will offer the Cryo-Vacc™ cases to the market on a monthly rental arrangement, including the maintenance, delivery, and collection of the Cryo-Vacc™ cases from respective maintenance points.

The three sizes offered currently include a large case (up to 2,400 vials), a medium case (up to 1,200 vials) and a smaller case (up to 240 vials) which is ideal for smaller vaccination points such as pharmacies and medical practices.

"This is an exciting time and another milestone for Renergen, and we look forward to working with DPD Laser in rolling out the Cryo-Vacc™.

"The prototype was put through its paces in a first validation phase and was purely focused on temperature distribution and stability. Notably, the Cryo-Vacc™ passed successfully. We saw areas where we could improve the design during this process and resubmitted it for another

round of validation yesterday. Many of the original components were replaced or improved upon. We do not anticipate updating the market with this validation, as it is merely a repeat of the previous validation using different components.

"We believe the technology works, and as time progresses, we will continue to enhance and improve the Cryo-Vacc™ as we gain valuable data from people in the field using the product. The analogy we see here is that version 12 of a smartphone was not the first version released; they got there over time. Cryo-Vacc™ will continue to evolve, and this is the exciting part as it becomes more flexible and useful in the field, which is the goal," said Reenergen CEO Stefano Marani.

DPD Laser CEO Anton Visagie said, *"We have the ideal solution, storage and distribution, given the current uncertainty on which vaccines will be used at various vaccination points across South Africa. Our technology can handle all three required temperatures of 2-8 degrees, -20 degrees and -70 degrees Celsius without being dependent on an external power supply for periods between 7 and 35 days."*

Johannesburg
20 April 2021

Authorised by: Stefano Marani
Chief Executive Officer

Designated Advisor
PSG Capital



PSG CAPITAL

For Australian Investors & Media, contact Citadel-MAGNUS
Cameron Gilenko, 0466 984 953

For South African Investors & Media, contact us on
info@reenergen.co.za
+2710 045 6007

www.reenergen.co.za